SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 9, 2016
(Exact name of registrant as specified in
|(State of other jurisdiction
||(Commission File Number)
14282 Franklin Avenue, Tustin, California 92780
|(Address of Principal Executive Offices)|
|Registrant’s telephone number, including area code: (714) 508-6000|
|(Former name or former address, if changed since last report)|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|ITEM 2.02||RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On March 9, 2016, Peregrine
Pharmaceuticals, Inc. (the “Company”) issued a press release to report the Company’s financial results for the
third quarter ended January 31, 2016. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
No additional information is included in this Current Report on Form 8-K.
The information included
in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed “filed” for purposes of, nor
shall it be deemed incorporated by reference in, any filing under the Securities Act of 1933 or the Securities Exchange Act of
1934, except as expressly set forth by specific reference in such a filing.
|| REGULATION FD DISCLOSURE|
On March 9, 2016, at
11:30 a.m. ET/8:30 a.m. PT, the Company will host a conference call to discuss its third quarter ended January 31, 2016 financial
results. The webcast of the conference call will be archived on the Company’s website for approximately 30 days.
|| FINANCIAL STATEMENTS AND EXHIBITS|
(d) Exhibits. The following material
is filed as an exhibit to this Current Report on Form 8-K:
||Press Release issued March
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
||PEREGRINE PHARMACEUTICALS, INC.|
|Date: March 9, 2016
Chief Financial Officer
| ||Exhibit Number
|| ||Press Release issued March 9, 2016